Catalysis can be leveraged to design enzyme inhibitors that are more potent and specific in targeting the enzymes responsible for glucose metabolism. For instance, inhibitors for the DPP-4 enzyme can prolong the half-life of incretin hormones, enhancing insulin secretion and lowering blood glucose levels. Additionally, catalytic processes can be employed to develop biocompatible materials for controlled drug delivery systems, ensuring a sustained release of medication.
